WLF to DOJ: clean up prosecution of drug promotion

Share this article:
The Washington Legal Foundation (WLF) called for the U.S. Department of Justice to rein in the Office of Consumer Litigation, which supervises cases involving alleged improper promotion by pharmaceutical firms and medical device manufacturers.
In a letter to deputy attorney general James Comey, the free-market think tank called on the Department of Justice to reassign oversight for cases involving drug promotion to its Criminal Division, which, the WLF said, "has far more expertise in addressing the sensitive issues inherent in any criminal investigation."
The WLF said that the OCL has failed to set clear standards regarding what forms of promotional activities are prosecutable.
"To date, OCL has failed to provide clear guidance and coordination," said the letter. "Indeed, OCL has left senior FDA officials largely in the dark regarding criminal investigations that it has approved."
Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.